Ignite Creation Date:
2025-12-25 @ 5:11 AM
Ignite Modification Date:
2025-12-26 @ 4:16 AM
Study NCT ID:
NCT02175927
Status:
COMPLETED
Last Update Posted:
2016-03-01
First Post:
2014-06-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2016-11-23', 'releaseDate': '2016-10-03'}], 'estimatedResultsFirstSubmitDate': '2016-10-03'}}, 'interventionBrowseModule': {'meshes': [{'id': 'D064747', 'term': 'Lansoprazole'}, {'id': 'D054328', 'term': 'Proton Pump Inhibitors'}, {'id': 'D001729', 'term': 'Bismuth'}, {'id': 'D008795', 'term': 'Metronidazole'}, {'id': 'D000900', 'term': 'Anti-Bacterial Agents'}, {'id': 'D000658', 'term': 'Amoxicillin'}, {'id': 'D013752', 'term': 'Tetracycline'}], 'ancestors': [{'id': 'D053799', 'term': '2-Pyridinylmethylsulfinylbenzimidazoles'}, {'id': 'D013454', 'term': 'Sulfoxides'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D001562', 'term': 'Benzimidazoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D020228', 'term': 'Pharmacologic Actions'}, {'id': 'D020164', 'term': 'Chemical Actions and Uses'}, {'id': 'D004603', 'term': 'Elements, Radioactive'}, {'id': 'D004602', 'term': 'Elements'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D019216', 'term': 'Metals, Heavy'}, {'id': 'D011868', 'term': 'Radioisotopes'}, {'id': 'D007554', 'term': 'Isotopes'}, {'id': 'D008670', 'term': 'Metals'}, {'id': 'D009593', 'term': 'Nitroimidazoles'}, {'id': 'D009574', 'term': 'Nitro Compounds'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D000890', 'term': 'Anti-Infective Agents'}, {'id': 'D045506', 'term': 'Therapeutic Uses'}, {'id': 'D000667', 'term': 'Ampicillin'}, {'id': 'D010400', 'term': 'Penicillin G'}, {'id': 'D010406', 'term': 'Penicillins'}, {'id': 'D047090', 'term': 'beta-Lactams'}, {'id': 'D007769', 'term': 'Lactams'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D013754', 'term': 'Tetracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 312}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-12', 'completionDateStruct': {'date': '2015-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-02-29', 'studyFirstSubmitDate': '2014-06-24', 'studyFirstSubmitQcDate': '2014-06-25', 'lastUpdatePostDateStruct': {'date': '2016-03-01', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-06-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Minimal inhibitory concentrations (MIC) of antibiotics against each helicobacter pylori clinical isolate', 'timeFrame': '2 months', 'description': 'Determine MIC of amoxicillin, tetracycline, and metronidazole by the twofold agar dilution method.'}], 'primaryOutcomes': [{'measure': 'Eradication rate of Helicobacter pylori', 'timeFrame': '2 months', 'description': 'Access eradication rate of H. pylori by intention to treat (ITT) and per-protocol (PP) analysis in each treatment group'}], 'secondaryOutcomes': [{'measure': 'Frequency of side effects of each treatment', 'timeFrame': '2 months', 'description': 'Score side effects as mild, moderate or severe according to their influence on daily activities'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Helicobacter pylori', 'Treatment Failure', 'second-line therapy'], 'conditions': ['Helicobacter Pylori Treatment Failure']}, 'referencesModule': {'references': [{'pmid': '22491499', 'type': 'BACKGROUND', 'citation': "Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084."}, {'pmid': '23778309', 'type': 'BACKGROUND', 'citation': 'Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1134-40. doi: 10.1097/MEG.0b013e3283633b57.'}]}, 'descriptionModule': {'briefSummary': 'No trial has examined the the efficacy of high dose amoxicillin based quadruple therapy as second-line treatment for Helicobacter pylori infection. The study aims to compare the effectiveness and safety of 14-day high dose amoxicillin-based quadruple regiment with classical quadruple regiment for rescue eradication of Helicobacter pylori.', 'detailedDescription': 'Helicobacter pylori is the most successful human pathogen infecting an estimated 50% of the global population, and is associated with a spectrum of disease states, including chronic gastritis, duodenal and gastric ulcer, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue lymphoma (MALToma).\n\nMost Consensus Conferences and Clinical Guidelines recommend the prescription of a triple therapy including a proton pump inhibitor (PPI) and clarithromycin with either amoxicillin or metronidazole, as first-line treatment. However, the effectiveness of these triple-therapy regimens seems to have diminished over time, largely as a result of emerging resistance of the organism to clarithromycin. Avoiding problems due to antibiotic resistance has become an important issue when deciding a second-line rescue therapy for H. pylori infection\n\nBismuth-containing quadruple therapies have been used widely in second-line therapy of H. pylori infection, and are recommended by the Maastricht IV Consensus Conference report. Quadruple therapy can achieve a high rate of eradication success as a second-line treatment. A meta-analysis of quadruple therapy showed that metronidazole resistance had limited effect on the outcome when adequate dosages and durations are used. This meta-analysis also showed that compliance with quadruple therapy is high. Classical bismuth-based quadruple therapy consists of a PPI, bismuth, tetracycline and metronidazole. This regiment meets the proposed criteria for a second-line treatment: it does not contain the key antibiotic of the original regimen (clarithromycin), the treatment is not affected by clarithromycin resistance, metronidazole resistance in vitro does not affect the outcome of quadruple therapy significantly, compliance with the regimen is high and the regimen is effective in most parts of the world. But this regiment has high rate of side effects because of tetracycline.\n\nAmoxicillin has low resistance rate as well as low percentage of side effects. The replacement of tetracycline by high dose amoxicillin in classical bismuth-containing quadruple therapy may be a better choice. Therefore, we will do a randomized trial to compare the eradication rate of 14-day high dose amoxicillin and metronidazole based bismuth-containing quadruple therapy with classical quadruple therapy for second-line Helicobacter pylori treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* all patients had failed H.pylori therapies including clarithromycin, metronidazole and/or amoxicillin (if not allergic) before\n* indication of rescue H pylori eradication treatment\n* Ability and willingness to participate in the study and to sign and give informed consent\n\nExclusion Criteria:\n\n* patients less than 18 years old\n* previous gastric surgery\n* pregnancy or lactation\n* major systemic diseases,\n* administration of antibiotics, bismuth, antisecretory drugs in the preceding 8 weeks\n* allergy to any one of the medication used in the quadruple regimens.'}, 'identificationModule': {'nctId': 'NCT02175927', 'briefTitle': 'High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection', 'organization': {'class': 'OTHER', 'fullName': 'Shanghai Jiao Tong University School of Medicine'}, 'officialTitle': 'Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection', 'orgStudyIdInfo': {'id': 'rjkls2014007'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'High Dose Amoxicillin', 'description': 'High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid', 'interventionNames': ['Drug: Lansoprazole', 'Drug: Bismuth Potassium Citrate', 'Drug: Metronidazole', 'Drug: Amoxicillin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Tetracycline', 'description': 'Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid', 'interventionNames': ['Drug: Lansoprazole', 'Drug: Bismuth Potassium Citrate', 'Drug: Metronidazole', 'Drug: Tetracycline']}], 'interventions': [{'name': 'Lansoprazole', 'type': 'DRUG', 'otherNames': ['proton pump inhibitor'], 'description': 'antisecretory drug of each quadruple therapy', 'armGroupLabels': ['High Dose Amoxicillin', 'Tetracycline']}, {'name': 'Bismuth Potassium Citrate', 'type': 'DRUG', 'otherNames': ['Bismuth'], 'description': 'one component of each quadruple therapy', 'armGroupLabels': ['High Dose Amoxicillin', 'Tetracycline']}, {'name': 'Metronidazole', 'type': 'DRUG', 'otherNames': ['antibiotic'], 'description': 'antibiotic of each quadruple therapy', 'armGroupLabels': ['High Dose Amoxicillin', 'Tetracycline']}, {'name': 'Amoxicillin', 'type': 'DRUG', 'otherNames': ['antibiotic'], 'description': 'antibiotic of high dose amoxicillin based quadruple therapy', 'armGroupLabels': ['High Dose Amoxicillin']}, {'name': 'Tetracycline', 'type': 'DRUG', 'otherNames': ['antibiotic'], 'description': 'antibiotic of classical quadruple therapy', 'armGroupLabels': ['Tetracycline']}]}, 'contactsLocationsModule': {'locations': [{'zip': '200127', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Shanghai Renji Hospital, Shanghai Jiao-Tong University School of Medicine', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'overallOfficials': [{'name': 'Hong Lu, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'RenJi Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shanghai Jiao Tong University School of Medicine', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor of GI Division', 'investigatorFullName': 'Hong Lu, MD', 'investigatorAffiliation': 'Shanghai Jiao Tong University School of Medicine'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2016-10-03', 'type': 'RELEASE'}, {'date': '2016-11-23', 'type': 'RESET'}], 'unpostedResponsibleParty': 'Hong Lu, MD, Professor of GI Division, Shanghai Jiao Tong University School of Medicine'}}}}